About SeaStar Medical Holding
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States.
The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis.
It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease.
SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.